Drug intelligence / Profile preview

WJ05

Development stage: Preclinical
Lead developer: Wigen Biomedicine Technology
Modality: Small Molecules
Administration: Oral

Overview

WJ05 is a small molecule inhibitor of the Wee1 kinase, currently under development by Wigen Biomedicine Technology (Shanghai). Wee1 is a nuclear kinase that serves as a critical regulator of the G2/M cell cycle checkpoint by phosphorylating and inactivating CDC2. By inhibiting Wee1, WJ05 prevents cancer cells from repairing DNA damage before entering mitosis, thereby inducing mitotic catastrophe and apoptosis. This mechanism is particularly effective in TP53-deficient tumors, which rely heavily on the G2 checkpoint for DNA repair. WJ05 is being investigated for the treatment of various oncology indications.

Targets

WEE1 (WEE1 G2 checkpoint kinase)

Beyond the preview

Go deeper on WJ05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WJ05.

Explore the full profile